HUTCHMED DRC
Price & Volume
Stats
See more52W Range | $9.77-$16.33 |
Market Cap | $2.3B |
Shares Short | 265,001 |
Financials
See moreRevenue (12 Mos) | $549.1M |
Revenue Growth (YoY) | 0.2% |
Gross Profit (12 Mos) | $73.1M |
Diluted EPS | $0.10 |
News
See moreYahoo Finance • 3 days ago
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
Yahoo Finance • 19 days ago
3 British Healthcare Stocks To Own In October 2026
Yahoo Finance • 23 days ago
How Investors May Respond To HUTCHMED (China) (AIM:HCM) US NDA For ORPATHYS–TAGRISSO Lung Cancer Combo
Yahoo Finance • last month
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
About
CEO | Mr. Chig Fung Cheng BEc, CA |
CFO | Mr. Chig Fung Cheng BEc, CA |
Address | Cheung Kong Center, Hong Kong, Hong Kong |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 1,790 |